Division of Urology, Department of Surgery, Penn State College of Medicine, Hershey, PA.
Pennsylvania State University, College of Medicine, Hershey, PA.
Clin Genitourin Cancer. 2019 Apr;17(2):132-138. doi: 10.1016/j.clgc.2018.11.009. Epub 2018 Nov 22.
The purpose of this study was to explore whether the practice of postoperative renal cell carcinoma (RCC) surveillance affords a survival benefit by investigating whether detection of RCC recurrences in an asymptomatic versus symptomatic manner influences mortality.
We identified 737 patients who underwent partial or radical nephrectomy for M0 RCC between 1998 and 2016. Overall survival and disease-specific survival stratified by the type of recurrence detection (asymptomatic vs. symptomatic) was estimated using Kaplan-Meier probabilities both from the time of surgery and from the time of recurrence. Cox proportional hazard regression models were used to evaluate the impact of the type of recurrence detection on mortality.
A total of 78 patients (10.6%) experienced recurrence after surgery, of whom 63 (80.8%) were asymptomatic (detected using routine surveillance) and 15 (19.2%) were symptomatic. The median postoperative follow-up was 47.2 months (interquartile range, 26.3-89.4 months). Five- and 10-year overall survival, from time of surgery, among patients with asymptomatic versus symptomatic recurrences was 57% and 39% versus 24% and 8%, respectively (P = .0002). As compared with asymptomatic recurrences, patients with symptomatic recurrences had an increased risk of overall (OD) and disease-specific death (DSD) both when examined from the time of surgery (OD: hazard ratio [HR], 3.16; 95% confidence interval [CI], 1.33-7.49; P = .0091 and DSD: HR, 3.44; 95% CI, 1.38-8.57; P = .0079) and from the time of recurrence (OD: HR, 2.93; 95% CI, 1.24-6.93; P = .0143 and DSD: HR, 3.62; 95% CI, 1.45-9.01; P = .0058).
Capturing RCC recurrences in an asymptomatic manner during routine surveillance is associated with improved patient survival.
本研究旨在探讨术后肾细胞癌(RCC)监测的实践是否具有生存获益,方法是研究以无症状方式与有症状方式检测到 RCC 复发是否会影响死亡率。
我们确定了 1998 年至 2016 年间接受部分或根治性肾切除术治疗 M0 RCC 的 737 例患者。使用 Kaplan-Meier 概率从手术时间和复发时间两个方面评估了复发检测类型(无症状 vs 有症状)分层后的总生存和疾病特异性生存。使用 Cox 比例风险回归模型评估了复发检测类型对死亡率的影响。
共有 78 例(10.6%)患者术后复发,其中 63 例(80.8%)为无症状(通过常规监测发现),15 例(19.2%)为有症状。术后中位随访时间为 47.2 个月(四分位距,26.3-89.4 个月)。在无症状复发和有症状复发患者中,从手术时间开始计算的 5 年和 10 年总生存率分别为 57%和 39%比 24%和 8%(P =.0002)。与无症状复发相比,有症状复发患者的总死亡(OD)和疾病特异性死亡(DSD)风险均增加,无论从手术时间(OD:风险比[HR],3.16;95%置信区间[CI],1.33-7.49;P =.0091 和 DSD:HR,3.44;95% CI,1.38-8.57;P =.0079)还是从复发时间(OD:HR,2.93;95% CI,1.24-6.93;P =.0143 和 DSD:HR,3.62;95% CI,1.45-9.01;P =.0058)来看。
在常规监测中以无症状方式捕捉 RCC 复发与改善患者生存相关。